Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

13.93
-0.0400-0.29%
Post-market: 13.930.00000.00%19:57 EDT
Volume:1.48M
Turnover:20.49M
Market Cap:1.21B
PE:-7.45
High:14.13
Open:13.72
Low:13.11
Close:13.97
52wk High:36.26
52wk Low:2.86
Shares:87.16M
Float Shares:71.89M
Volume Ratio:0.52
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8700
EPS(LYR):-1.8700
ROE:-36.61%
ROA:-21.42%
PB:2.54
PE(LYR):-7.45

Loading ...

LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Mar 21

Olema Pharmaceuticals Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 20

Olema Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Mar 18

Stock Track | Olema Pharmaceuticals Plummets 5.01% Intraday After Goldman Sachs Slashes Price Target

Stock Track
·
Mar 18

Olema Oncology price target raised to $58 from $55 at JPMorgan

TIPRANKS
·
Mar 18

Olema Oncology price target lowered to $27 from $38 at Goldman Sachs

TIPRANKS
·
Mar 18

Olema Pharmaceuticals to present two preclinical posters at AACR Annual Meeting

Reuters
·
Mar 18

Olema Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Mar 17

Guggenheim Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Mar 17

Olema Oncology price target raised to $62 from $60 at Citi

TIPRANKS
·
Mar 17

Olema Pharmaceuticals: Palazestrant Phase III Upside and Differentiated Pipeline Underpin Buy Rating

TIPRANKS
·
Mar 17

Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
Mar 17

Olema Pharmaceuticals Shares Rise on Narrower Loss Per Share in 2Q

Dow Jones
·
Mar 17

Buy Rating Reaffirmed on Palazestrant’s Differentiated Phase 3 Program and Favorable Risk‑Reward Profile for Olema

TIPRANKS
·
Mar 16

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Weigh Tech Rally Against Geopolitical Risks

MT Newswires Live
·
Mar 16

Olema Pharmaceuticals Q4 EPS $(0.50) Beats $(0.53) Estimate

Benzinga
·
Mar 16

Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs

Reuters
·
Mar 16

Olema Q4 net loss widens 37.2% to USD 46.06 million

Reuters
·
Mar 16

BRIEF-Olema Pharmaceuticals Q4 Net Income USD -46.061 Million

Reuters
·
Mar 16

Olema Pharmaceuticals Q4 EPS USD -0.5

THOMSON REUTERS
·
Mar 16